GSK, XenoPort revise Horizant pact

Just a few days after the FDA accepted GlaxoSmithKline's ($GSK) response to its complete response letter on Horizant for review, XenoPort ($XNPT) announced that it had revised its development pact with GSK on the new therapy for restless leg syndrome. XenoPort retrieved ex-U.S. rights to the therapy, while leaving GSK in charge of the U.S. market. In a statement the developer also said that the two partners had revised the terms of the deal, but no numbers were outlined. The FDA had rejected Horizant after noting signs of cancer in a rat study. XenoPort release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.